21721-92-6

Nitrefazole is an inhibitor of aldehyde dehydrogenase useful in the management of alcoholism. Cited advantages over disulfiram include longer duration of action, higher specificity (no inhibition of dopamine β-hydroxylase) and fewer side effects. It is generally recognized that the efficacy of such agents with respect to permanent abstinence is low. However, temporary abstinence and/or controlled drinking may facilitate supportive psychotherapy and/or delay the onset of severe alcoholic diseases.

E. Merck (W. Germany)

Nitrefazole is a nitroimidazole derivative with the ability to inhibit aldehyde dehydrogenase, and enzyme crucial to the metabolism of alcohol. This compound is suitable for aldehyde dehydrogenase (ALDH) related research.

ChEBI: Nitrefazole is a member of imidazoles.

ALTIMOL

Nitrefazole, which is used in the treatment of alcoholism, was introduced in the early 1980s. By 1984 its use had been associated with hepatotoxic reactions, some of which were fatal. This led to its withdrawal in at least two countries. WHO has no information to suggest that preparations containing nitrefazole remain commercially available.